Evidence map›Paper›PMID 41089495›Full record

ReviewACS medicinal chemistry letters2025

Recent Advancements in 20S Proteasome Enhancement: Degradation of Undruggable Targets.

Sydney G Cobb, Jetze J Tepe

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in ACS medicinal chemistry letters, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Sydney G CobbDepartment of Chemistry, University of Virginia, Charlottesville, Virginia 22904, United States.ORCID https://orcid.org/0009-0005-0553-2043
Jetze J TepeDepartment of Chemistry, University of Virginia, Charlottesville, Virginia 22904, United States.ORCID https://orcid.org/0000-0001-5467-5589

Funding

Small molecule induced proteolytic destruction of intrinsically disordered proteinsR01AG066223 · NIA · MICHIGAN STATE UNIVERSITY · PI TEPE, JETZE J. · 2019 to 2022
$1.7M
Development of cellular HTS for 20S proteasome enhancersR61NS111347 · NINDS · MICHIGAN STATE UNIVERSITY · PI LISABETH, ERIKA MATHES, NEUBIG, RICHARD R · 2020 to 2021
$699k
Overcoming proteasome impairment with small moleculesR21AG076994 · NIA · UNIVERSITY OF VIRGINIA · PI TEPE, JETZE J. · 2022 to 2022
$389k
Development of Cellular HTS for 20S Proteasome EnhancersR33NS111347 · NINDS · MICHIGAN STATE UNIVERSITY · PI LISABETH, ERIKA MATHES, NEUBIG, RICHARD R · 2022 to 2022
$384k
NIA NIH HHS R01 AG066223NIA NIH HHS R21 AG076994NINDS NIH HHS R33 NS111347NINDS NIH HHS R61 NS111347
6 · The paper itself

Abstract

The ubiquitin-independent proteasome system has emerged as an attractive point of intervention for a variety of diseases, including neurodegenerative diseases. Though inhibition of this system has been studied for decades, 20S proteasome enhancement is much younger by comparison, but substantial levels of progress have been made in this field especially within the last five years. This microperspective will highlight these advancements, focusing on the novel developments being made in designing potent enhancers and evaluating them in disease-relevant systems.

Indexed as

20S proteasomeintrinsically disordered proteinsneurodegenerative diseasesproteasome enhancersprotein degradation

Identifiers

PMID41089495
PMCPMC12516374

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.